Literature DB >> 11509620

Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against gram-negative bacteria.

D Le Roy1, F Di Padova, Y Adachi, M P Glauser, T Calandra, D Heumann.   

Abstract

LPS-binding protein (LBP) and CD14 potentiate cell activation by LPS, contributing to lethal endotoxemia. We analyzed the contribution of LBP/CD14 in models of bacterial infection. Mice pretreated with mAbs neutralizing CD14 or LBP showed a delay in TNF-alpha production and died of overwhelming infection within 24 h, after a challenge with 250 CFU of virulent Klebsiella pneumoniae. Blockade of TNF-alpha also increased lethality, whereas pretreatment with TNF-alpha protected mice, even in the presence of LBP and CD14 blockade. Anti-LBP or anti-CD14 mAbs did not improve or decrease lethality with a higher inoculum (10(5) K. pneumoniae) and did not affect outcome following injections of low or high inocula of Escherichia coli O111. These results point to the essential role of LBP/CD14 in innate immunity against virulent bacteria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509620     DOI: 10.4049/jimmunol.167.5.2759

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms.

Authors:  Lutz Hamann; Christian Alexander; Cordula Stamme; Ulrich Zähringer; Ralf R Schumann
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Influence of lipopolysaccharide-binding protein on pulmonary inflammation in gram-negative pneumonia.

Authors:  Michael A Taddonio; Vladislav Dolgachev; Markus Bosmann; Peter A Ward; Grace Su; Stewart C Wang; Mark R Hemmila
Journal:  Shock       Date:  2015-06       Impact factor: 3.454

4.  CD14 contributes to warm hepatic ischemia-reperfusion injury in mice.

Authors:  Changchun Cai; Xiaolian Shi; Sebastian Korff; Jinxiang Zhang; Patricia A Loughran; Xiangcai Ruan; Yong Zhang; Li Liu; Timothy R Billiar
Journal:  Shock       Date:  2013-08       Impact factor: 3.454

5.  Intestinal damage mediated by Kupffer cells in rats with endotoxemia.

Authors:  Jian-Ping Gong; Chuan-Xin Wu; Chang-An Liu; Sheng-Wei Li; Yu-Jun Shi; Kang Yang; Yue Li; Xu-Hong Li
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 6.  Markers of bacterial translocation in end-stage liver disease.

Authors:  Ioannis Koutsounas; Garyfallia Kaltsa; Spyros I Siakavellas; Giorgos Bamias
Journal:  World J Hepatol       Date:  2015-09-18

7.  Plasma Proteome Signature of Sepsis: a Functionally Connected Protein Network.

Authors:  Genaro Pimienta; Douglas M Heithoff; Alexandre Rosa-Campos; Minerva Tran; Jeffrey D Esko; Michael J Mahan; Jamey D Marth; Jeffrey W Smith
Journal:  Proteomics       Date:  2019-02-20       Impact factor: 3.984

8.  Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4.

Authors:  Thierry Roger; Céline Froidevaux; Didier Le Roy; Marlies Knaup Reymond; Anne-Laure Chanson; Davide Mauri; Kim Burns; Beat Michel Riederer; Shizuo Akira; Thierry Calandra
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-30       Impact factor: 11.205

9.  Escherichia coli and Staphylococcus aureus elicit differential innate immune responses following intramammary infection.

Authors:  Douglas D Bannerman; Max J Paape; Jai-Wei Lee; Xin Zhao; Jayne C Hope; Pascal Rainard
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

10.  Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice.

Authors:  Sylvia Knapp; Alex F de Vos; Sandrine Florquin; Douglas T Golenbock; Tom van der Poll
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.